Translational efforts must prioritise the development of highly specific OGT/OGA inhibitors or allosteric modulators and rigorously validate their efficacy – particularly in rational combination regimens – within preclinical models that recapitulate human tumour heterogeneity and therapy resistance. This evidence concerns the gene OGT and neoplasm.